Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease
Medicina · 27.03.2026 · 62 (4) · 639
DOI: 10.3390/medicina62040639 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicina, online erschienen am 27.03.2026. Verfasst von Evangelia Fouka und 4 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 124 62 Rimini, Gree…. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by reduced circulating levels and/or impaired function of alpha-1 antitrypsin (AAT), a key serine protease inhibitor, in which loss of effective antiprotease protection results in unchecked neutrophil elastase activity and progressive lung tissue destruction. Although AATD accounts for approximately 1% of chronic obstructive pulmonary disease (COPD) cases and up to 2% of emphysema, AATD-related COPD remains largely underdiagnosed, despite guideline recommendations for systematic evaluation in patients with COPD, particularly in high-risk clinical settings. Pathologically, AATD-related COPD is not limited to the typical early-onset, lower-lobe-predominant emphysema, also including upper-lobe or mixed emphysema patterns, airway-predominant disease, small airways dysfunction, and bronchiectasis. Clinically, AATD-related COPD is distinguished from smoking-related COPD by its earlier onset, physiological impairment that is often disproportionate to smoking exposure, and its potential presence of certain extrapulmonary manifestations. Diagnosis and monitoring are also challenged by the frequent discordance between airflow limitation and gas transfer impairment, as well as the early involvement of small airways, limiting reliance on spirometry alone. A multimodal assessment incorporating more sensitive functional techniques and CT densitometry may provide a more precise evaluation of disease burden, progression, and prognosis. Management generally follows standard COPD principles, with intravenous AAT augmentation therapy remaining currently the only established disease-modifying therapy for selected patients with severe deficiency. The advent of new pharmacological and gene-based therapies emphasizes the importance of developing personalized management strategies that integrate genotype and longitudinal disease behavior. This narrative review summarizes current evidence on AATD-associated COPD, focusing on its genetic basis and pathophysiological features, clinical and functional heterogeneity, current and emerging diagnostic and monitoring approaches, and disease-specific management considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 124 62 Rimini, Greece.
ORCID-Profile: Evangelia Fouka, Argyro Vrouvaki, Stelios Loukides
Zitieren
APA
Fouka, E., Vrouvaki, A., Moustaka Christodoulou, M., Loukides, S., & Hillas, G. (2026). Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease. Medicina, 62(4), 639. https://doi.org/10.3390/medicina62040639
Vancouver
Fouka E, Vrouvaki A, Moustaka Christodoulou M, Loukides S, Hillas G. Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease. Medicina. 2026;62(4):639. doi:10.3390/medicina62040639
BibTeX
@article{Fouka2026,
author = {Fouka, Evangelia and Vrouvaki, Argyro and Moustaka Christodoulou, Marina and Loukides, Stelios and Hillas, Georgios},
title = {Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease},
journal = {Medicina},
year = {2026},
volume = {62},
number = {4},
pages = {639},
doi = {10.3390/medicina62040639}
}
EUVIMED